BioMotiv announces new startup: Anti-cancer drug developer Z53 Therapeutics
The company is looking to create drugs that will tackle cancer tumors with p53 protein mutations.
BioAtla-BioMotiv licensing deal results in new biotech startup to develop IBD, cancer drugs
There’s a new biotech startup in town: Kodosil Bio. The by-product of a licensing deal between San Diego biologics developer BioAtla and Cleveland-based biotech incubator BioMotiv, the company will focus on development of a monoclonal antibody for inflammatory bowel diseases and cancers. For now, details are pretty scant on the new company. According to a […]
Dual Therapeutics forms to develop new cancer therapeutics discovered at Mount Sinai
A $250 million drug discovery initiative launched last year at University Hospitals of Cleveland has produced its second startup, this one based on cancer research from the Icahn School of Medicine at Mount Sinai. Dual Therapeutics will develop new treatments for prostate cancer, lung cancer and acute lymphoblastic leukemia, according to an announcement today from […]
Biotech accelerator BioMotiv, NYU unveil a new spinoff for inflammatory disease treatments
A biotech accelerator launched as part of a $250 million drug discovery initiative spearheaded by Cleveland’s University Hospitals has spun off its first company to develop promising technology for treating inflammatory diseases. Orca Pharmaceuticals is the first company announced by BioMotiv, the for-profit accelerator associated with the Harrington Discovery Project at UH. BioMotiv in- licenses […]
The biotech valley of death has become the uncrossable canyon. Here’s one innovative approach to funding
We often talk about innovation in terms of science and technology, but in today’s healthcare ecosystem, it’s just as important to innovate on the business side of things. That’s what the $250 million Harrington Project for Discovery & Development, a national initiative based at University Hospitals Case Medical Center, is trying to do. It comprises […]